Compare HNNA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNNA | PLRX |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | 18 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 70.6M |
| IPO Year | N/A | 2020 |
| Metric | HNNA | PLRX |
|---|---|---|
| Price | $10.15 | $1.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 4.9K | ★ 437.4K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.57% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.90 | $1.09 |
| 52 Week High | $13.19 | $1.95 |
| Indicator | HNNA | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 43.54 |
| Support Level | $9.71 | $1.12 |
| Resistance Level | $10.28 | $1.37 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 63.83 | 26.67 |
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.